In this issue:
MRI biomarker for remyelinated lesions in MS
Long-term treatment with ponesimod in RRMS
Association of sNfL with inner retinal layer thinning in MS
sNfL as a predictor of 10-year grey matter atrophy and clinical disability in MS
Time to first treatment and risk of disability pension in RRMS
Age-specific effects of childhood BMI on MS risk
Progression is independent of relapse activity in early MS
Predictors of progression from a FDE to clinically definite MS
Increase in age of onset of RRMS over the last five decades
Ocrelizumab extended interval dosing in RRMS
Please login below to download this issue (PDF)